[go: up one dir, main page]

FR15C0047I1 - - Google Patents

Info

Publication number
FR15C0047I1
FR15C0047I1 FR15C0047C FR15C0047I1 FR 15C0047 I1 FR15C0047 I1 FR 15C0047I1 FR 15C0047 C FR15C0047 C FR 15C0047C FR 15C0047 I1 FR15C0047 I1 FR 15C0047I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0047(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR15C0047I1 publication Critical patent/FR15C0047I1/fr
Application granted granted Critical
Publication of FR15C0047I2 publication Critical patent/FR15C0047I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR15C0047C 2002-04-16 2015-07-03 Antagonistes tricycliques du recepteur de thrombine Active FR15C0047I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16
PCT/US2003/011510 WO2003089428A1 (en) 2002-04-16 2003-04-14 Tricyclic thrombin receptor antagonists

Publications (2)

Publication Number Publication Date
FR15C0047I1 true FR15C0047I1 (de) 2015-08-28
FR15C0047I2 FR15C0047I2 (fr) 2016-05-06

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0047C Active FR15C0047I2 (fr) 2002-04-16 2015-07-03 Antagonistes tricycliques du recepteur de thrombine

Country Status (34)

Country Link
US (3) US7304078B2 (de)
EP (5) EP1495018B3 (de)
JP (2) JP4558331B2 (de)
KR (1) KR101026929B1 (de)
CN (1) CN1659162B (de)
AR (1) AR039570A1 (de)
AT (3) ATE455774T1 (de)
AU (1) AU2003221932B2 (de)
BR (1) BRPI0309309B8 (de)
CA (1) CA2482858C (de)
CY (3) CY1107184T1 (de)
DE (3) DE60317493T3 (de)
DK (2) DK2065384T3 (de)
EC (1) ECSP045368A (de)
ES (3) ES2357876T3 (de)
FR (1) FR15C0047I2 (de)
HK (3) HK1070887A1 (de)
IL (1) IL164585A (de)
LT (1) LTC1495018I2 (de)
LU (1) LU92759I2 (de)
MX (1) MXPA04010308A (de)
MY (1) MY144040A (de)
NL (1) NL300746I1 (de)
NO (2) NO330500B1 (de)
NZ (2) NZ535880A (de)
PE (1) PE20040412A1 (de)
PL (1) PL214718B1 (de)
PT (2) PT2065384E (de)
RU (2) RU2329264C9 (de)
SG (1) SG164279A1 (de)
SI (2) SI2065384T1 (de)
TW (1) TWI343919B (de)
WO (1) WO2003089428A1 (de)
ZA (1) ZA200408342B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
MXPA06013903A (es) * 2004-05-28 2007-01-26 Schering Corp Analogos restringidos de himbacina como antagonistas del receptor de trombina.
AU2005294265A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
US7772276B2 (en) * 2005-01-14 2010-08-10 Schering Corporation Exo-selective synthesis of himbacine analogs
AR052870A1 (es) * 2005-01-14 2007-04-11 Schering Corp Sintesis de analogos de himbacina
CA2594742A1 (en) * 2005-01-14 2006-07-20 Schering Corporation Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
DE602006012450D1 (de) * 2005-01-14 2010-04-08 Schering Corp Exo- und diastereoselektive synthese von himbacin-analoga
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
TWI316937B (en) 2005-03-31 2009-11-11 Schering Corp Spirocyclic thrombin receptor antagonists
US20070219154A1 (en) * 2005-12-20 2007-09-20 Suxing Liu Methods for preventing and/or treating a cell proliferative disorder
JP2009521472A (ja) * 2005-12-22 2009-06-04 シェーリング コーポレイション 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
EP2007755B1 (de) * 2006-04-13 2012-06-27 Schering Corporation Kondensierte ringthrombinrezeptor-antagonisten
JP2009542662A (ja) * 2006-06-29 2009-12-03 シェーリング コーポレイション 置換二環系および置換三環系トロンビン受容体アンタゴニスト
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
AU2007305269A1 (en) * 2006-10-04 2008-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
AR063095A1 (es) * 2006-10-04 2008-12-30 Schering Corp Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina
EP2120879A2 (de) * 2006-12-22 2009-11-25 Schering Corporation Desintegrationspromoter in nassgranulat-formulierungen mit fester dosierung
BRPI0809095A2 (pt) * 2007-03-23 2014-09-09 Schering Corp Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina
MY152040A (en) 2008-02-05 2014-08-15 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
PL2240486T3 (pl) 2008-02-05 2016-02-29 Sanofi Sa Sole triazoliowe jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako lek
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
TW201008930A (en) 2008-05-19 2010-03-01 Schering Corp Heterocyclic compounds as factor IXa inhibitors
WO2010141525A1 (en) 2009-06-04 2010-12-09 Schering Corporation Active metabolite of a thrombin receptor antagonist
MX2011013091A (es) 2009-06-08 2012-01-12 Schering Corp Un antagonista del receptor de trombina y tableta con dosificacion fija de clopidogrel.
US8609676B2 (en) 2009-08-04 2013-12-17 Merck Sharp & Dohme, Corp. 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
ES2532902T3 (es) 2010-04-16 2015-04-01 Sanofi Piridil-vinil-pirroles tricíclicos como inhibidores de PAR1
EP2558462B1 (de) 2010-04-16 2014-10-22 Sanofi Pyridyl-vinyl-pyrazolo-chinoline als par1-inhibitoren
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
EP2822557B1 (de) 2012-03-06 2017-08-23 Merck Sharp & Dohme Corp. Herstellung und verwendung bicyclischer himbacinderivate als par-rezeptor-antagonisten
EP3024550A4 (de) 2013-07-22 2016-12-07 Merck Sharp & Dohme Co-kristall aus dem par-1-rezeptor-antagonisten vorapaxar und aspirin
EP3035928B1 (de) 2013-08-22 2023-10-18 Merck Sharp & Dohme LLC 3 -pyridyl-substituierte 6,6-difluor-bicyclische himbacinderivate
EP3035929B1 (de) 2013-08-22 2024-07-03 Merck Sharp & Dohme LLC 7a-amid-substituierte bicyclische 6,6-difluorhimbacinderivate
WO2015026685A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TW201738221A (zh) * 2016-04-22 2017-11-01 Jiangsu Tasly Diyi Pharmaceutical Co Ltd 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
EP4185587A1 (de) 2020-07-22 2023-05-31 JANSSEN Pharmaceutica NV Verbindungen als faktor-xia-hemmer
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
ZA9810685B (en) * 1997-11-25 1999-12-23 Schering Corp Thrombin receptor antagonists.
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
EP2301930B1 (de) 2000-06-15 2016-01-06 Merck Sharp & Dohme Corp. Für Behandlung von unter anderem Autoimmun- oder entzündlichen Erkrankungen geeignete Derivate von Hexahydrobezofuranon
PE20030808A1 (es) 2001-10-18 2003-09-22 Schering Corp Derivados triciclicos heterociclicos como antagonistas receptores de trombina

Also Published As

Publication number Publication date
JP2010132710A (ja) 2010-06-17
DE60317493D1 (en) 2011-01-13
NL300746I2 (de) 2016-01-21
EP1982984A3 (de) 2008-10-29
ES2297150T7 (es) 2012-03-16
DE60317493T2 (de) 2008-09-18
KR101026929B1 (ko) 2011-04-04
NO2015016I1 (no) 2015-07-20
EP2065384A1 (de) 2009-06-03
MY144040A (en) 2011-07-29
NL300746I1 (de) 2016-01-21
CA2482858A1 (en) 2003-10-30
US7304078B2 (en) 2007-12-04
PT2065384E (pt) 2011-03-16
CY2015029I1 (el) 2016-04-13
HK1129893A1 (en) 2009-12-11
CY2015029I2 (el) 2016-04-13
DK1495018T3 (da) 2008-02-18
EP1495018B3 (de) 2011-03-16
NZ535880A (en) 2007-11-30
DE60335679D1 (de) 2011-02-17
RU2008106401A (ru) 2009-08-27
ATE455774T1 (de) 2010-02-15
ZA200408342B (en) 2006-05-31
AU2003221932B2 (en) 2007-11-22
NO2015016I2 (no) 2015-07-09
MXPA04010308A (es) 2005-02-03
IL164585A (en) 2010-11-30
LTC1495018I2 (lt) 2017-04-10
US20030216437A1 (en) 2003-11-20
PE20040412A1 (es) 2004-07-12
JP2005528406A (ja) 2005-09-22
PL214718B1 (pl) 2013-09-30
TWI343919B (en) 2011-06-21
EP1860106B1 (de) 2010-01-20
ECSP045368A (es) 2005-01-03
US20070270439A1 (en) 2007-11-22
HK1070887A1 (en) 2005-06-30
NZ575139A (en) 2010-08-27
CY1111363T1 (el) 2015-08-05
EP1495018B1 (de) 2007-11-14
PT1495018E (pt) 2008-02-19
ATE494284T1 (de) 2011-01-15
BRPI0309309B8 (pt) 2021-05-25
RU2329264C2 (ru) 2008-07-20
AU2003221932A1 (en) 2003-11-03
BR0309309A (pt) 2005-02-15
EP1982984B1 (de) 2013-02-13
DE60317493T3 (de) 2018-07-12
ES2338171T3 (es) 2010-05-04
RU2004133375A (ru) 2005-07-10
EP1495018A1 (de) 2005-01-12
CN1659162B (zh) 2011-08-31
FR15C0047I2 (fr) 2016-05-06
PL373332A1 (en) 2005-08-22
HK1123302A1 (en) 2009-06-12
TW200404068A (en) 2004-03-16
DE60331114D1 (de) 2010-03-11
WO2003089428A1 (en) 2003-10-30
US20070179187A1 (en) 2007-08-02
SG164279A1 (en) 2010-09-29
SI2065384T1 (sl) 2011-05-31
NO330500B1 (no) 2011-05-02
ES2357876T3 (es) 2011-05-03
CY1107184T1 (el) 2012-10-24
US7713999B2 (en) 2010-05-11
KR20040099441A (ko) 2004-11-26
ES2297150T3 (es) 2008-05-01
BRPI0309309B1 (pt) 2018-09-04
EP2062890B1 (de) 2011-01-05
JP4558331B2 (ja) 2010-10-06
RU2329264C9 (ru) 2009-04-20
LU92759I2 (en) 2015-08-31
EP2062890A1 (de) 2009-05-27
DK2065384T3 (da) 2011-05-02
AR039570A1 (es) 2005-02-23
EP1982984A2 (de) 2008-10-22
EP2065384B1 (de) 2011-01-05
ATE378330T1 (de) 2007-11-15
CN1659162A (zh) 2005-08-24
IL164585A0 (en) 2005-12-18
EP1860106A1 (de) 2007-11-28
NO20044963L (no) 2004-11-15
CA2482858C (en) 2010-11-30
SI1495018T1 (sl) 2008-04-30

Similar Documents

Publication Publication Date Title
BE2019C547I2 (de)
BE2019C510I2 (de)
BE2018C021I2 (de)
BE2017C049I2 (de)
BE2017C005I2 (de)
BE2016C069I2 (de)
BE2016C013I2 (de)
BE2015C078I2 (de)
BE2016C002I2 (de)
BE2018C018I2 (de)
FR15C0047I1 (de)
BE2013C039I2 (de)
BE2013C025I2 (de)
BE2011C038I2 (de)
JP2003188402A5 (de)
JP2003190159A5 (de)
JP2003182329A5 (de)
JP2003234757A5 (de)
JP2002265425A5 (de)
JP2003224106A5 (de)
JP2003251257A5 (de)
JP2003234474A5 (de)
BR0315835A2 (de)
JP2003228061A5 (de)
JP2002355971A5 (de)